4SC AG: 7 upcoming conferences

Planegg-Martinsried (pta010/25.02.2021/07:30 UTC+1)

4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation in upcoming financial and scientific conferences. 4SC’s management and/or scientists will be available for personal contact at these events.

ESMO Targeted Anticancer Therapies Virtual Congress 2021: the Home of Phase I in Oncology

1 - 2 March 2021

Virtual Congress

Bio-EUROPE Spring

22 - 25 March 2021

Virtual Congress

AACR ANNUAL MEETING 2021

10 - 15 April 2021

Virtual Congress

10th World Congress of Melanoma and 17th EADO Congress

15 - 17 April 2021

Virtual Congress

Digital 4th Neoantigen Summit Europe 2021

20 - 22 April 2021

Virtual Congress

2021 Annual ASCO Meeting

4 - 8 June 2021

Virtual Congress

BIO Digital

10 - 11 June 2021

Virtual Congress

- Announcement ends -

Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 46 employees as of 30 September 2020 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

ir-pr@4sc.com
+49 89 700763-0

(end)

Emitter:	4SC AG Fraunhoferstr. 22 82152 Planegg-Martinsried Germany
Contact Person:	4SC AG
Phone:	+49 89 700763-0
E-Mail:	ir-pr@4sc.com
Website:	www.4sc.de
ISIN(s):	DE0005753818 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate